Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Powell

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.
Toxicologic Pathology|August 24, 2011
Induction of heart valve lesions by small-molecule ALK5 inhibitorsMark J Anderton, Howard R Mellor, Alex Bell, et al.
The American Surgeon|July 11, 2003
Popliteal artery trauma in a rural level I trauma centerScott G Sagraves, Anne M Conquest, Robert J Albrecht, et al.
Angiogenesis|May 31, 2012
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologiesMatthew Farren, Susie Weston, Helen Brown, et al.
Oncotarget|May 14, 2019
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumoursLiliana D Ordonez, Trevor Hay, Robert McEwen, et al.
Human Mutation|October 20, 2011
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor typesSiân Jones, Meng Li, D Williams Parsons, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft ModelsM Raymond V Finlay, Mark Anderton, Andrew Bailey, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.
Toxicologic Pathology|August 24, 2011
Induction of heart valve lesions by small-molecule ALK5 inhibitorsMark J Anderton, Howard R Mellor, Alex Bell, et al.
The American Surgeon|July 11, 2003
Popliteal artery trauma in a rural level I trauma centerScott G Sagraves, Anne M Conquest, Robert J Albrecht, et al.
Angiogenesis|May 31, 2012
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologiesMatthew Farren, Susie Weston, Helen Brown, et al.
Oncotarget|May 14, 2019
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumoursLiliana D Ordonez, Trevor Hay, Robert McEwen, et al.
Human Mutation|October 20, 2011
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor typesSiân Jones, Meng Li, D Williams Parsons, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft ModelsM Raymond V Finlay, Mark Anderton, Andrew Bailey, et al.
Pageof 2